300003 乐普医疗
2025/03 - 三个月
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入1,736,231-9.67%6,103,2697,979,89910,609,44210,659,735
减:营业总成本1,321,826-1.09%5,522,1186,354,8877,926,7478,207,653
    其中:营业成本624,607-1.86%2,387,6472,853,2863,983,2864,156,637
               财务费用33,2823,726.23%42,24484,92992,578171,760
               资产减值损失(2,271)592.08%(287,867)(165,092)(37,953)(9,448)
公允价值变动收益937-72.56%3893,0924,42029,340
投资收益19,649-557.74%(89,713)(16,533)(75,335)(396,883)
    其中:对联营企业和合营企业的投资收益19,656-224.29%(65,950)(24,361)(90,833)(152,254)
营业利润468,448-23.11%253,1391,547,2152,623,1392,144,602
利润总额464,905-23.44%225,7611,554,4982,611,7822,146,152
减:所得税费用87,691-23.38%28,467262,147365,726365,733
净利润377,214-23.45%197,2941,292,3512,246,0551,780,419
减:非控股权益(1,326)-112.18%(49,644)34,15142,27661,094
股东净利润378,540-21.44%246,9381,258,2002,203,7791,719,325

市场价值指针
每股收益 (元) *0.205-20.86%0.1340.6761.2230.960
每股派息 (元) *----0.2770.3310.3410.275
每股净资产 (元) *8.189-4.71%7.9698.3817.9406.239
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容